VRE Endocarditis Treatment — EECC MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Linezolid or daptomycin-based regimen with infectious disease specialist input — VRE endocarditis is a challenging infection requiring prolonged combination therapy, often including surgical valve replacement
VRE (vancomycin-resistant Enterococcus, predominantly E. faecium) endocarditis is a rare but serious infection with limited treatment options. The 2023 ESC IE Guidelines recommend: (1) linezolid (good tissue penetration, bacteriostatic — concern about long-term myelosuppression); (2) daptomycin (bactericidal for enterococci at high doses, good for biofilm — but monitor for CPK elevation); (3) combination therapy (daptomycin + ampicillin, or linezolid + gentamicin/rifampicin) may be synergistic; (4) tigecycline (bacteriostatic, limited evidence). Infectious disease specialist involvement is essential. Surgical valve replacement is frequently needed due to: poor antibiotic response, prosthetic valve involvement (higher failure rate with medical therapy alone), and abscess formation. VRE IE has a mortality rate of 30-50%.
Reference: ESC (2023): IE Guidelines; IDSA VRE Guidelines